MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] MT1013.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
\[14C\] MT1013/MT1013 Injection
The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
Jinan, Shandong, China
Cumulative excretion of radioactivity
Time frame: Day 1 to Day 91.
Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)
Time frame: Day 1 to Day 91.
Adverse Events (AEs)
Time frame: About 13 weeks.
Serious adverse Events (SAEs)
Time frame: About 13 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.